MB301

MB301 is a preclinical-stage bispecific peptide being developed by Mainline Biosciences for the treatment of pain. It features a dual mechanism of action, functioning as both a neurokinin-1 (NK1) receptor antagonist and a mu-opioid receptor (MOR) agonist. This bifunctional approach is designed to provide potent analgesic effects through opioid receptor activation while potentially mitigating common opioid-related side effects and enhancing efficacy through the inhibition of NK1 receptors, which are involved in pain transmission and neurogenic inflammation. Mainline Biosciences, based in Malvern, Pennsylvania, is advancing this therapeutic as part of its pipeline focused on pain management and opioid-related conditions.